>Year 2009, Issue 3
Rodríguez RJ, Montes OSMA, Villalobos SJA, Domínguez JS, Granillo JF
Use of activated factor VII in critically ill patients: Experience with 54 cases
Rev Asoc Mex Med Crit y Ter Int 2009; 23 (3)
PDF: 71.75 Kb.
Introduction: Severe bleeding in the critically ill patient is an entity that often increases time of hospitalization and mortality. Use of recombinant activated factor VII (rFVIIa) has shown to be effective to treat hemorrhage with a low rate of adverse effects.
Objective: To report the experience of using rFVIIa in critically ill patients from the Intensive Care Unit (ICU) of The ABC Medical Center, Mexico City.
Design: An observational, transversal and retrospective study from a database of 54 critically ill patients treated with rFVIIa in the ICU.
Results: Etiology of bleeding: Surgical 50%, hematologic 22%, vascular 16.7%, multifactorial 11.3%, APACHE II 16.6 ± 6.5 (6-30), 22% of total patients were infected, general mortality of 35.2%, amount of doses necessaries to stop bleeding: Survivors: 336 mL/h pre dose and 45 mL/h post dose, Non survivors: 290 mL/h pre dose and 66 mL/h post dose.
Conclusion: Administration of rFVIIa in critically ill patients was coincidental with a lowering rate of bleeding.
||Recombinant activated factor VII, critically ill patient, bleeding.
Abbas A, Yalcin S, Serdaroglu H et al. Prophylaxis with recombinant activated factor VII (rFVIIa) for minimally invasive surgery in a patient with congenital factor VII deficiency: a case report with a single low dose of rFVIIa. Fibrinolysis 2008;19:693-695.
Hsia C, Chin Yee I, Mc Alister V. Use of recombinant activated factor VII in patients without hemophilia. Ann Surg 2008;248:61-68.
Mistakos G, Papaioannou G, Giougi E et al. Is the use of rFVIIa state and effective in bleeding neonates? J Pediatr Hematol Oncol 2007;29(3):145-150.
Kheirabadi BS, Delgado A, Dubick M et al. In vitro effect of activated recombinant factor VII on coagulation properties of human hypothermic temperatures. J Trauma 2007;63:1079-1086.
Diringer M, Skolnick B, Mayer S et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008;39:850-856.
Giansily-Blaizot M, Biron-Andreani C, Aguilar-Martínez P, de Moeloose Philippe, Briquel Marie-E, Goudemand J et al. Inherited factor VII deficiency, and surgery. Clinical data are the best criteria to predict the risk of bleeding. Br J Haematol 2002;117:172-175.
Tanaka KA, Waly AA, Cooper WA, Levy JH. Treatment of excessive bleeding in Jehovah’s Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 2003;98:1513-1515.
Brown SA. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Hemophilia 2005;11:430-431.
Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: therapy with recombinant activated factor VII–a critical appraisal. Haemophilia 2006;12:19-27.
Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. Hematology 2007;12:55-62.
Tobias J, Berkenbosch J, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003;4:49-51.
Millar CG, Stringer MD, Sugarman I et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005;11:171-174.
Hedner U. Mechanism of action of recombinant activated factorVII: an update. Semin Hematol 2006;43(suppl 1): 105-107.
>Year 2009, Issue 3